Users Discontinuing Anti-Obesity Injections Put On Weight Four Times Faster Compared to Those on Conventional Diets

A recent study suggests that individuals who stop using new slimming jabs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt traditional diet and exercise regimens.

Research printed in a leading health publication points out that while obese people can lose about a fifth of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"Users using these medications must be informed of the potential of fast rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.

That rate of recovery means a reversion to original mass within about a year and a half.

Weighing Therapies

The analysis, which looked at 37 of studies involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.

Researchers emphasize that people who shed pounds through diet and exercise typically see a less rapid creep back—approximately 100 grams monthly—once they finish.

Understanding the Quick Regain

Doctors suggest the mode of action of the drugs explains the accelerated weight return.

These medications mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.

"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the body to produce less of its own natural GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.

"Stopping of this medication results in hunger is uncontrolled, making overeating far more likely."

A Chronic Disease?

The NHS suggest the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.

Professionals say that, given the likelihood of weight regain, the therapy should be considered long-term.

This view is supported by pharmaceutical companies, who note that the results "emphasize the persistent character of obesity," akin to managing conditions like diabetes.

User Experiences

Individuals who have come off the jabs report a intense resurgence of cravings.

"It felt as if a trigger flipping and you're instantly extremely hungry," said an individual.

This challenge is compounded if users have not established lasting dietary or behavioural modifications during therapy.

Widespread Use

Survey data suggest that millions of people in the UK have used these injections in the past year, with desire being substantial.

• Adoption is more common among women compared to males.
• The 40s and 50s age group shows the highest usage rates.
• A large proportion obtain the medications through private prescriptions rather than the NHS.

In conclusion, experts caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and long-term success relies on integrated behavioural support.